Sign in
Taking peoplePhase 2

A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder.

Key facts

Who runs it
Bioprojet Pharma
Where
Italy, Poland, Portugal, and Spain20 sites in 4 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
54 people, planned
Started
12 Jan 2026
Expected to end
29 Feb 2028
Type of study
Interventional
Record updated
7 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Written informed consent obtained prior to any trial-related procedures
  • Male or female ≥18-75 years old
  • Primary diagnosis of OCD for ≥ 1 year with or without previous or current tic, as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision. Participant must have good/fair insight of their condition where he or she recognizes obsessions/compulsions are excessive or unreasonable
  • Moderate to severe OCD: Current total YBOCS-II score of ≥ 22 at screening and randomization, with no more than 35% of improvement or worsening in the score from screening to randomization visit
  • Participants who are receiving evidence-based pharmacologic treatment for OCD at an appropriate therapeutic dose and duration and demonstrate only a partial/insufficient response (i.e., failure to achieve clinically significant symptom improvement)
  • Participants must have had stable doses of concomitant psychiatric medications for at least 8 weeks prior to screening and at least 12 weeks prior to randomization
  • Participants must have a cooperative attitude and be able to understand and comply with the entire trial requirements and procedures (e.g., trial-related questionnaire, drug compliance, not use prohibited concomitant medications)
  • Female participant: post-menopausal woman having at least 12 months of natural (spontaneous) amenorrhea without any alternative medical cause, or woman of childbearing potential (WOCBP, defined as all fertile women, following menarche and until becoming post-menopausal unless permanently sterile; permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) using a highly effective method of contraception for the duration of the trial and for one (1) month after stopping the investigational medication
  • If required, participant must be insured by appropriate national health insurance system

Who cannot take part

  • Current or prior history of schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autism spectrum disorders, intellectual disability, dementia, or mild/severe neurocognitive disorder, borderline personality disorder, and antisocial personality disorder
  • Concomitant prolactin-dependent tumour (e.g., pituitary tumour or breast cancer)
  • Electroconvulsive therapy (ECT) or Transcranial Magnetic Stimulation (TMS) in the past 3 months
  • Participant with unstable concurrent uncontrolled or unstable disease that might affect the participant’s safety and/or interfere with the conduct of the trial according to the Investigator’s judgement
  • Participant having received any other investigational drug within the preceding 30 days, or a longer and more appropriate time as determined by the Investigator (e.g., approximately five half-lives of the previous investigational drug)
  • Psychological (e.g., supportive psychotherapy, cognitive behaviour therapy, interpersonal therapy) intervention for OCD that was begun within the 3 months before trial entry. Participants on such treatment for more than 3 months prior to screening may be enrolled if they agree not to make any changes to the frequency or nature of their treatment during the course of the trial
  • Participants with poor or absent/delusional insight of their OCD condition per DSM-5-TR, i.e., participants who think their obsessions/compulsions are likely reasonable or hold delusional convictions about them
  • Unstable/uncontrolled bipolar I or II disorder
  • Current (or in the last 1 year) main diagnosis of Tourette's disorder, body dysmorphic disorder, hoarding disorder, impulse control disorder, body-focused repetitive behaviours (e.g., skin picking disorder, trichotillomania), anorexia nervosa or any other eating disorder
  • Documented resistance to antipsychotic augmentation: Participants with well-documented nonresponsiveness to antipsychotic augmentation within the past 2 years, defined as a failure to achieve clinically significant symptom improvement relative to their pre-augmentation baseline following the addition of an antipsychotic to an ongoing OCD pharmacotherapy regimen at an appropriate therapeutic dose and duration. Participants who discontinued antipsychotic augmentation prematurely or did not receive a full therapeutic trial/duration (for any reason) are not considered exclusionary under this criterion
  • Participants who are unable or unlikely to maintain a stable dose of their current, approved OCD medication(s) throughout the trial, including those anticipated to require initiation of a new pharmacologic regimen (e.g., switch between SSRIs or to/from clomipramine, or augmentation) during the study period, or with a history of non-adherence to psychiatric medications
  • History of hypersensitivity to any of the trial drug constituents
  • Any history of Substance-Related and Addictive Disorders (excluding nicotine and caffeine)
  • Brain damage, or other cognitive impairment that would interfere with the capacity to participate in the trial and complete measures
  • Participant with a clinically significant deviation(s) from normal on 12-lead ECG that results in an active medical problem, as determined by the Investigator at screening or has a corrected QT interval using Fridericia’s formula (QTcF) ≥450 msec for males or ≥470 msec for females
  • Participant who has a laboratory abnormality at screening as follows: _ALT, AST values > 2 x ULN _Serum creatinine value >1.5 x ULN _GFR < 50 mL/min/1.73 m² (CKD-EPI formula) _Absolute neutrophils count <1.0x109 /L _Platelets < 100x109 /L _or who has any other uncontrolled clinically significant laboratory abnormalities that would affect interpretation of the trial data or the participant’s participation in the trial. Note: one retest will be allowed during the screening period if the investigator believes the abnormality is transient and not clinically significant
  • Female participants: pregnant or lactating women. [Pregnancy is confirmed by a positive serum human chorionic gonadotrophin laboratory test (> 5mIU/mL). Serum pregnancy test will be done at screening and urine test at randomisation]
  • History of significant cardiovascular disease, particularly recent history of myocardial infarction or unstable coronary artery disease, arrhythmias, congestive heart failure, uncontrolled arterial hypertension. Participant with a known history of long QT syndrome with or without history of syncope
  • Participants who had psychosurgery or have a Deep Brain Stimulation (DBS)
  • Participants who are on unstable dose of anxiolytics, hypnotics, or daridorexant, and are unwilling, or its not clinically possible, to maintain a stable dose during the trial
  • To the opinion of the investigator, participants who may be uncooperative, or who are in particular legal, non-legal, or life circumstances that could prevent them from adhering to the trial protocol, should be excluded
  • Regular (daily or weekly) use of psychoactive cannabis with tetrahydrocannabinol (i.e., including non-psychoactive cannabidiol), or hallucinogens [e.g., lysergic acid diethylamide (LSD), psilocybin (“magic mushrooms”), 3,4-Methylenedioxymethamphetamine (MDMA), ibogaine, dimethyltryptamine (DMT), ayahuasca, non-prescribed ketamine/esketamine, etc.]
  • Active suicidality (i.e., any suicide attempts in the past 12 months or any ongoing suicidal intent, as assessed by the C-SSRS score of “YES” on questions 4 or 5; and/or based on clinical evaluation by the investigator)

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective is to evaluate the safety, tolerability, and efficacy of BP1.4979 in treating OCD.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder
Record updated
7 September 2026